Cellix Bio Pvt Ltd. is a biopharmaceutical company, which engages in the development and discovery of novel drugs. It specializes in the treatment of neurology, dermatology, gastrointestinal, inflammation, metabolic and life style, oncology, ophthalmology, and infectious diseases. The company was founded by Mahesh Kandula on May 21, 2014 and is headquartered in Hyderabad, India.

Sydnexis is engaged in the development of a proprietary treatment for pediatric progressive myopia, a major global unmet medical need. Sydnexis manufactures pharmaceutical product for ophthalmic disorder or condition.

Allergan, Inc. operated as a global healthcare company. It engaged in the development and commercialization of specialty pharmaceutical, medical device ,and over-the-counter products for the ophthalmic, neurological, medical aesthetics, medical dermatology, breast aesthetics, obesity intervention, urological, and other specialty markets. The company was founded by Gavin S. Herbert in 1950 and headquartered in Irvine, CA.

Alcon, Inc. engages in the development, manufacture, and marketing of market surgical equipment and devices, pharmaceutical eye drops, and consumer vision care products to treat eye diseases and disorders. It operates through the following segments: Surgical and Vision Care. The Surgical segment offers implantable products, consumables and equipment for use in surgical procedures to address cataracts, vitreoretinal conditions, refractive errors, and glaucoma. The Vision Care segment comprises daily disposable, reusable and color-enhancing contact lenses, as well as portfolio of ocular health products, including over-the-counter products for dry eye, contact lens care, and ocular allergies, as well as ocular vitamins and redness relievers. The company was founded by Mr. Robert Alexander and Mr. William Conner on 1945 and is headquartered in Geneva, Switzerland.

Oyster Point Pharma is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of first-in-class pharmaceutical therapies to treat ocular surface diseases. Oyster Point Pharma’s lead product candidate, OC-01, a highly selective nicotinic acetylcholine receptor (nAChR) agonist, is being developed as a nasal spray to treat the signs and symptoms of dry eye disease. Dry eye disease is a chronic, progressive condition that impacts more than 30 million Americans and is growing in prevalence. OC-01’s novel mechanism of action re-establishes tear film homeostasis by activating the trigeminal parasympathetic pathway to stimulate the glands and cells responsible for natural tear film production, known as the Lacrimal Functional Unit (LFU).

Founded in 1994, Quark devoted its early years to developing its innovative technology platform for identification of novel functional target genes and proteins, the “BiFAR” technology. The basic concept, patented by Quark, of high throughput gene inactivation combined with microarray detection of the functional genes responsible for the occurrence of phenotypes of interest, was at that time revolutionary. With the advent of siRNA technology, Quark's approach is rapidly becoming the technology of choice for functional studies industry-wide. We have applied our BiFAR platform in gene discovery programs in serious diseases with significant unmet medical needs, often in collaboration with large pharmaceutical partners. Today we are harvesting the fruits of the innovative targets and concepts we identified.

Kodiak Sciences is designing and developing novel therapies for the treatment of retinal disease. As a rapidly growing biopharmaceutical company, we are working every day to build value for the benefit of our community of patients, physicians, employees, families, and vendors. We want to have real impact, and we take a long term view. We are committed to ethics and excellence in everything we do. We are looking to hire top talent comfortable with ownership and accountability of exciting programs while collaborating effectively with colleagues inside and outside the company.

Glaxo Group Ltd. operates through its subsidiary Glaxo Laboratories Ltd. that engages in the production of food products for infants such as Ostermilk, Complan, Casilan, Farex. Glaxo Group Ltd. was formerly known as Glaxo Laboratories Ltd. and changed its name to Glaxo Group Ltd. in 1962. The company is based in Brentford, United Kingdom. Glaxo Group Ltd. operates as a subsidiary of Glaxosmithkline plc.

Sight Sciences is a medical device company that uses a computer-based device designed for the treatment of eye disease. Sight Sciences' devices and non-invasive dry eye products are used for glaucoma procedures or in combination with cataract surgery using the same clear corneal incision, assisting ophthalmologists and optometrists to address the underlying physiology of ophthalmic disease. The company's non-surgical Dry Eye product portfolio consists of TearCare which is now commercially available for both ophthalmologists and optometrists. TearCare is a software-controlled, wearable eyelid technology that delivers highly targeted and adjustable heat to the meibomian glands of the eyelids for conditions such as meibomian gland dysfunction and dry eye. It was founded in 2011 and is headquartered in Menlo Park, California, United States.

Genentech is a biotechnology company that discovers, develops, manufactures, and commercializes medicines to treat patients with serious or life-threatening medical conditions. It creates multiple products on the market and a development pipeline. The company became a member of the Roche Group in 2009. As part of their merger agreement, Roche and Genentech combined their pharmaceutical operations in the United States. Genentech’s South San Francisco campus now serves as the headquarters for Roche pharmaceutical operations in the United States. Genentech’s Research and Early Development section operates as an independent center within Roche. Genentech was founded in 1976 by [Robert Swanson](https://www.crunchbase.com/person/robert-a-swanson) and [Herbert Boyer](https://www.crunchbase.com/person/herbert-w-boyer). It is headquartered in South San Francisco, C.A.

OccuRx, a Melbourne-based biopharmaceutical company, was established in 2014 with venture funding from the Medical Research Commercialisation Fund, Brandon Capital Partners and Uniseed. The Company’s primary focus is on the development of innovative therapeutic strategies for the treatment of ophthalmic disorders associated with retinal fibrosis.

NatureWise Biotech & Medicals Corp. engages in the wholesale and retail of Chinese and Western medicines and medical equipment. Its business includes retailing of category B patent medicine, food and beverage; and biotechnology service industry. Its products and services include new drug development, antitumor drugs, and retinopathy drugs. It specializes in Taiwanese Green Propolis Series and Red Yeast Rice Series. The company was founded on December 29, 2000 and is headquartered in Taipei, Taiwan.

Dongguan Songhu Technology Co., Ltd., established on 2013-04-16, Business scope includes biotechnology,information Technology,electronic product,other chemical products(Free of Hazardous Chemicals),Technical research and development of mechanical equipment,technology transfer,Technical Consulting and Technical Services;Medical Research;Laboratory analysis equipment,Technical development of monitoring instruments and equipment;Sales:biomaterials,3D printing consumables,3D printing equipment,Laboratory testing reagents and equipment;laboratory equipment,Reagent,Consumables Testing Services;research and development,technology transfer,Sales:smart equipment,Computer hardware and software,3D scanner,3D printer,engraving pen,General mechanical equipment and accessories;Computer Information System Integration;Business Management Consulting Services;Intelligent Manufacturing Technology Consulting,Technical Services,Technology transfer;Import and export of goods or technology(Except for the import and export of goods and technologies that are prohibited by the state or involve administrative approval);software,Automation equipment,Development of automated systems,Engineering installation;Intelligent electromechanical and information product design,manufacture,Leasing and Sales.(Items subject to approval by law,Business activities can only be carried out after approval by relevant departments)

Suzhou Sunkel Biomedical Technology Co., Ltd., established on 2012-05-04, Business scope includes biotechnology,Technology research and development in the field of medical device technology,technical consulting,Technical Services;Sales:medical instruments,Equipment,communication equipment,experimental reagent,optical equipment,Instrumentation,Computers and Accessories,Glasses and Accessories,cosmetic,Health Supplies,Daily necessities,Cleaning Products,handcrafted gift,plastic products,rubber products,Labor protection supplies,Office Supplies;Optometry.(Items subject to approval by law,Business activities can only be carried out after approval by relevant departments) licensed items:Import and export;Technology Import and Export(Items subject to approval by law,Business activities can only be carried out after approval by relevant departments,Specific business projects are subject to approval results)

Novartis AG is a holding company, which engages in the development, manufacture, and marketing of healthcare products. It operates through the following segments: Innovative Medicines, Sandoz, and Corporate. The Innovative Medicines segment researches, develops, manufactures, distributes and sells patented pharmaceuticals, and is composed of two business units: Novartis Oncology and Novartis Pharmaceuticals. The Sandoz segment develops, manufactures and markets finished dosage form medicines as well as intermediary products, including active pharmaceutical ingredients. The Corporate segment refers to group management and central services. The company was founded on February 29, 1996 and is headquartered in Basel, Switzerland.

Sinopsee Therapeutics Pte Ltd. is a Singaporean private company. The firm operates as bio-pharmaceutical company.

Acceleron Pharma, Inc. operates as a biopharmaceutical company. The company engages in developing, manufacturing, and commercializing novel biotherapeutics that modulate the growth of bone, muscle, fat, and the vasculature to treat musculoskeletal, metabolic, and cancer-related diseases. Its products include ACE-011 Program, a novel bone forming agent that helps to treat cancer-related bone loss; ACE-031 Program that helps to treat diseases involving the loss of muscle mass, strength, and function in diseases, including muscular dystrophy, amyotrophic lateral sclerosis, and cancer-related muscle loss; and ACE-041, a protein therapeutic that binds a member of the growth and differentiation factor family necessary for angiogenesis. It develops therapies based on growth and differentiation factors that regulate the cellular proliferation, differentiation, and survival of a range of tissue types. The company offers treatments for cancer-related bone loss, cancer-related muscle loss, neuromuscular diseases, and metabolic disorders. Acceleron Pharma, Inc. was founded in 2003 and is headquartered in Cambridge, Massachusetts.

Santen Pharmaceutical Co., Ltd engages in the manufacture and sale of pharmaceutical products and medical devices. It operates through the following segments: Pharmaceuticals and Others. The Pharmaceuticals segment includes prescription ophthalmic drugs, anti-rheumatic pharmaceuticals, and over-the-counter products. The Others segment offers medical equipment and devices. The company was founded by Kenkichi Tagushi in 1890 and is headquartered in Osaka, Japan.

Guangzhou Eye-catching Pharmaceutical Technology Co., Ltd., established on 2013-03-01, Business scope includes natural science research and experimental development;Health Consulting Services(Does not include medical services);Sales of special labor protection products;Paper Products Manufacturing;Paper Products Sales;Disinfectant sales(Free of Hazardous Chemicals);Daily necessities sales;Daily necessities wholesale;Sales of Class I Medical Devices;Production of Class I Medical Devices;Sales of Class II Medical Devices;housing lease;Office equipment rental service;Non-residential real estate leases;internet sales(Except for products that require a license for sale);Personal Hygiene Sales;Chemical product sales(No licensed chemical products);Manufacturing of daily necessities;Daily miscellaneous goods sales;daily mask(non-medical)Sales;daily mask(non-medical)Production;General merchandise sales;Sales of daily chemical products;Manufacturing of daily chemical products;Sales of hygiene products and single-use medical products;Cosmetics Wholesale;Production of hygiene products and single-use medical products;Food Internet Sales;Class III medical device business;Import and export of goods managed by state trade;Cosmetic production;Production of Class II Medical Devices